ArticleCancer immunology, immunotherapy : CII2026
IAR025, a novel anti-DLL3 x CD3-bispecific antibody, displays high antitumor efficacy in preclinical models of small-cell lung cancer.
Yang Liu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.